MA53130A - Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada) - Google Patents
Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada)Info
- Publication number
- MA53130A MA53130A MA053130A MA53130A MA53130A MA 53130 A MA53130 A MA 53130A MA 053130 A MA053130 A MA 053130A MA 53130 A MA53130 A MA 53130A MA 53130 A MA53130 A MA 53130A
- Authority
- MA
- Morocco
- Prior art keywords
- drug
- ada
- interference mitigation
- immunological assay
- mitigation methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696016P | 2018-07-10 | 2018-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53130A true MA53130A (fr) | 2021-05-19 |
Family
ID=67544324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053130A MA53130A (fr) | 2018-07-10 | 2019-07-09 | Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200018770A1 (fr) |
| EP (1) | EP3821255A1 (fr) |
| JP (1) | JP2024045646A (fr) |
| KR (1) | KR20210031854A (fr) |
| CN (1) | CN112384808A (fr) |
| AU (1) | AU2019301614A1 (fr) |
| BR (1) | BR112020022912A2 (fr) |
| CA (1) | CA3098206A1 (fr) |
| EA (1) | EA202190237A1 (fr) |
| IL (1) | IL277888A (fr) |
| MA (1) | MA53130A (fr) |
| MX (1) | MX2021000331A (fr) |
| SG (1) | SG11202011283TA (fr) |
| WO (1) | WO2020014194A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220156023A (ko) * | 2020-03-17 | 2022-11-24 | 리제너론 파아마슈티컬스, 인크. | 항-약물 항체 검정에서의 표적 간섭 완화 |
| CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
| WO2024044622A1 (fr) * | 2022-08-24 | 2024-02-29 | Amgen Inc. | Dosages d'anticorps anti-médicament |
| CN115586337A (zh) * | 2022-09-14 | 2023-01-10 | 杭州赛基生物科技有限公司 | 检测肿瘤伴随诊断相关因子的试剂盒及其制备方法 |
| WO2024064044A1 (fr) * | 2022-09-23 | 2024-03-28 | Merck Sharp & Dohme Llc | Procédé de dosage d'anticorps de neutralisation |
| CN117805382B (zh) * | 2024-02-28 | 2024-05-03 | 军科正源（北京）药物研究有限责任公司 | 检测抗利妥昔单抗中和抗体的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6454356A (en) * | 1987-08-26 | 1989-03-01 | Meidensha Electric Mfg Co Ltd | Method for suppressing non-specific adsorption of antibody to solid phase antigen |
| WO2009022001A1 (fr) * | 2007-08-16 | 2009-02-19 | Novartis Ag | Amélioration de la tolérance à un médicament dans un test d'immunogénicité |
| WO2012175741A2 (fr) * | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques permettant de prédire, détecter et réduire une interférence protéinique spécifique dans des dosages impliquant des domaines variables uniques d'immunoglobuline |
| RU2674996C2 (ru) * | 2013-07-04 | 2018-12-14 | Ф. Хоффманн-Ля Рош Аг | Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки |
| MX2016010413A (es) * | 2014-02-11 | 2016-11-30 | Genzyme Corp | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco. |
| WO2017096262A1 (fr) * | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions et procédés pour atténuer ou prévenir une réponse immunitaire à une molécule thérapeutique immunogène chez des primates non humains |
| US20190145985A1 (en) * | 2017-11-10 | 2019-05-16 | BioAgilytix Labs, LLC | Method for eliminating target interference |
| JP7161534B2 (ja) * | 2017-11-29 | 2022-10-26 | エフ．ホフマン－ラ ロシュ アーゲー | 標的による干渉が抑制された抗薬物抗体アッセイ |
-
2019
- 2019-07-09 MA MA053130A patent/MA53130A/fr unknown
- 2019-07-09 MX MX2021000331A patent/MX2021000331A/es unknown
- 2019-07-09 CA CA3098206A patent/CA3098206A1/fr active Pending
- 2019-07-09 KR KR1020207033049A patent/KR20210031854A/ko not_active Application Discontinuation
- 2019-07-09 EP EP19749872.8A patent/EP3821255A1/fr active Pending
- 2019-07-09 EA EA202190237A patent/EA202190237A1/ru unknown
- 2019-07-09 BR BR112020022912-1A patent/BR112020022912A2/pt unknown
- 2019-07-09 WO PCT/US2019/040950 patent/WO2020014194A1/fr unknown
- 2019-07-09 US US16/506,379 patent/US20200018770A1/en active Pending
- 2019-07-09 CN CN201980046236.XA patent/CN112384808A/zh active Pending
- 2019-07-09 AU AU2019301614A patent/AU2019301614A1/en active Pending
- 2019-07-09 SG SG11202011283TA patent/SG11202011283TA/en unknown
-
2020
- 2020-10-08 IL IL277888A patent/IL277888A/en unknown
-
2024
- 2024-02-20 JP JP2024023599A patent/JP2024045646A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020014194A1 (fr) | 2020-01-16 |
| BR112020022912A2 (pt) | 2021-02-23 |
| MX2021000331A (es) | 2021-03-25 |
| CA3098206A1 (fr) | 2020-01-16 |
| CN112384808A (zh) | 2021-02-19 |
| AU2019301614A1 (en) | 2020-10-22 |
| US20200018770A1 (en) | 2020-01-16 |
| JP2021531448A (ja) | 2021-11-18 |
| KR20210031854A (ko) | 2021-03-23 |
| IL277888A (en) | 2020-11-30 |
| SG11202011283TA (en) | 2020-12-30 |
| EP3821255A1 (fr) | 2021-05-19 |
| EA202190237A1 (ru) | 2021-04-15 |
| JP2024045646A (ja) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53130A (fr) | Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada) | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA52091A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA44783A (fr) | Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4 | |
| MA52416A (fr) | Anticorps b7-h4 et leurs procédés d'utilisation | |
| MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation | |
| MA51902A (fr) | Schémas posologiques d'anticorps b7-h4 | |
| MA46814B2 (fr) | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet | |
| MA53328A (fr) | Anticorps anti-siglec-5 et leurs procédés d'utilisation | |
| MA53811A (fr) | Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation | |
| IL262514A (en) | Pharmaceutical preparations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| MA50516A (fr) | Anticorps anti-apoc3 et leurs procédés d'utilisation | |
| MA42706A (fr) | Anticorps et dosages pour la détection de cd37 | |
| MA54089A (fr) | Anticorps anti-pd-1 humain et procédés d'utilisation associés | |
| FR3052255B1 (fr) | Dispositif de pesee et systeme de determination de la masse et du centre de gravite d'un aeronef |